AU2002223983A1 - Diastereomeric peptides and pharmaceutical compositions comprising them - Google Patents

Diastereomeric peptides and pharmaceutical compositions comprising them

Info

Publication number
AU2002223983A1
AU2002223983A1 AU2002223983A AU2398302A AU2002223983A1 AU 2002223983 A1 AU2002223983 A1 AU 2002223983A1 AU 2002223983 A AU2002223983 A AU 2002223983A AU 2398302 A AU2398302 A AU 2398302A AU 2002223983 A1 AU2002223983 A1 AU 2002223983A1
Authority
AU
Australia
Prior art keywords
lysine
treatment
diastereomeric peptides
leucine
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002223983A
Inventor
Nurit Eyal
Ziv Oren
Michal Shahar
Yechiel Shai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of AU2002223983A1 publication Critical patent/AU2002223983A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463—Organic compounds; Microorganisms; Enzymes
    • A23L3/3526—Organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention provides diastereomeric peptides with a net positive charge greater than +1, and cyclic analogues thereof, having at least 15 amino acid residues, wherein said residues are selected from: (i) leucine and lysine;, (ii) leucine, lysine and arginine; (iii) glycine, serine, spargine, threonine, or glutamine optionally present at the N-terminus; (iv) and/or lysine, arginine, glycine, or serine optionally present at the C-terminus. The diastereomeric peptides are suitable for treatment of cancer and for treatment, particularly topical treatment, of infections caused by pathogenic organisms such as bacteria and fungi. In addition, they may be used for controlling, mycoplasma infection in cell cultures and for food preservation as food supplements and as alternative to antibiotics for animal nutrition.
AU2002223983A 2000-11-16 2001-11-07 Diastereomeric peptides and pharmaceutical compositions comprising them Abandoned AU2002223983A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL13972000A IL139720A0 (en) 2000-11-16 2000-11-16 Diastereomeric peptides and pharmaceutical compositions comprising them
IL139720 2000-11-16
PCT/IL2001/001036 WO2002040529A2 (en) 2000-11-16 2001-11-07 Diastereomeric peptides and pharmaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
AU2002223983A1 true AU2002223983A1 (en) 2002-05-27

Family

ID=11074825

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002223983A Abandoned AU2002223983A1 (en) 2000-11-16 2001-11-07 Diastereomeric peptides and pharmaceutical compositions comprising them

Country Status (7)

Country Link
US (1) US20040053847A1 (en)
EP (1) EP1334124B1 (en)
AT (1) ATE350395T1 (en)
AU (1) AU2002223983A1 (en)
DE (1) DE60125809T2 (en)
IL (2) IL139720A0 (en)
WO (1) WO2002040529A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312694B1 (en) * 1998-07-13 2001-11-06 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
EP1633380A4 (en) * 2003-06-19 2010-08-11 Yeda Res & Dev Antimicrobial and anticancer lipopeptides
US20090275503A1 (en) * 2005-09-22 2009-11-05 Yeda Research And Developent Co., Ltd. At The Weizman Institute Of Science Diastereomeric peptides for modulating t cell immunity
AU2006329535A1 (en) * 2005-12-27 2007-07-05 Yeda Research And Development Co. Ltd. Histidine-containing diastereomeric peptides and uses thereof
KR101899552B1 (en) * 2016-11-18 2018-09-17 군산대학교 산학협력단 Antimicrobial Peptide Analogues Derived From The Abalone, Haliotis Discus, And Antimicrobial Pharmaceutical Composition Containing The Same
DE102018003906A1 (en) 2018-05-07 2019-11-07 Smart Material Printing Use of polyoxometalates against the infestation of eukaryotic cultures, viral cultures and microorganism populations by mollicutes and mollicutene-inhibiting and killing polyoxometalate-containing substances and processes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665030B2 (en) * 1991-09-13 1995-12-14 Magainin Pharmaceuticals, Inc. Biologically active amphiphilic peptide compositions and uses therefor
US5643559A (en) * 1991-10-30 1997-07-01 Colgate-Palmolive Company Deodorant compositions comprising inhibitors of odor-producing axillary bacterial exoenzymes
WO1994005313A1 (en) * 1992-08-31 1994-03-17 Magainin Pharmaceuticals Inc. Treatment of gynecological malignancies with biologically active peptides
IL117223A0 (en) * 1996-02-22 1996-06-18 Yeda Res & Dev Antipathogenic polypeptides and compositions comprising them
EA199900752A1 (en) * 1997-02-20 2000-06-26 Йеда Рисерч Энд Дивелопмент Ко. Лтд. ANTIPATOGENIC SYNTHETIC PEPTIDES AND COMPOSITIONS INCLUDING THEM
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides

Also Published As

Publication number Publication date
US20040053847A1 (en) 2004-03-18
IL139720A0 (en) 2002-02-10
DE60125809T2 (en) 2007-10-11
WO2002040529A3 (en) 2003-03-20
DE60125809D1 (en) 2007-02-15
IL155910A (en) 2006-10-31
WO2002040529A2 (en) 2002-05-23
EP1334124B1 (en) 2007-01-03
EP1334124A2 (en) 2003-08-13
ATE350395T1 (en) 2007-01-15

Similar Documents

Publication Publication Date Title
Shafer et al. Human lysosomal cathepsin G and granzyme B share a functionally conserved broad spectrum antibacterial peptide.
WO2006006195B1 (en) Antibacterial peptides and analogues thereof
US20090005300A1 (en) Antimicrobial Peptides and Methods of Use
IL175319A0 (en) Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
EP3479824A3 (en) Peptides and their use
NZ595037A (en) Inhibition of biofilm organisms by combination of cysteamine and repetitive peptides
WO1996040768A2 (en) Anti-fungal and anti-bacterial histatin-based peptides
Harris et al. Anionic antimicrobial peptides from eukaryotic organisms and their mechanisms of action
EA199900752A1 (en) ANTIPATOGENIC SYNTHETIC PEPTIDES AND COMPOSITIONS INCLUDING THEM
Shafer et al. Bactericidal activity of a synthetic peptide (CG 117-136) of human lysosomal cathepsin G is dependent on arginine content
MX2020010071A (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria.
Huo et al. Selective activities of STAMPs against Streptococcus mutans
TWI403330B (en) Low hemolysis antibacterial peptide pharmaceutical compositions and use thereof
AU2002223983A1 (en) Diastereomeric peptides and pharmaceutical compositions comprising them
WO2007093848A3 (en) Crystalline enoyl-(acyl-carrier-protein) reductase from heliobacter pylori
WO2006123926A3 (en) Peptide composition for growing and/or culturing micro-organisms and/or cells
EP2409579A1 (en) Antimicrobial peptide, branched forms and uses thereof for the cure of bacteria infections
KR101444261B1 (en) A new scolopendrasin i peptide isolated from the scolopendra subspinipes and its synthetic composition
US5217956A (en) Composition and treatment with biologically active peptides and certain anions
WO2009005798A3 (en) Antifungal formulation and method of preparation
WO2008079314A3 (en) Novel anti-microbial peptidomimetic compounds and methods to calculate anti-microbial activity
MX2023003688A (en) Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability.
RU2008106460A (en) ANTI-MICROBIAL AGENT INTERACTING WITH THE KIT SYSTEM
Kukowska et al. In vitro studies of antimicrobial activity of Gly-His-Lys conjugates as potential and promising candidates for therapeutics in skin and tissue infections